Madrigal Pharmaceuticals Inc Sustainability Reports
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH), including its lead product Rezdiffra.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300CHIMT2EUSNJB60
FIGI: BBG001SNKQ42
2 reports from 2025 to 2025
